Desidustat in the Management of COVID-19 Patients

This is a phase 2b, multicenter, open-label, randomized, comparator-controlled clinical trial to evaluate the efficacy and safety of Desidustat for the management of COVID-19 patients. First 12 mild to moderate subjects (Test arm: Desidustat + Standard of care arm, 06 subjects and Reference arm: Standard of care, 06 subjects) will be enrolled in the study and after evaluation of safety of these 12 subjects by Data Monitoring Committee other 12 severe subjects (Test arm: Desidustat + Standard of care arm, 06 subjects and Reference arm: Standard of care arm, 06 subjects) will be enrolled in the study.

Inclusion criteria

• Ability to comprehend and willingness to sign a written ICF by the subject/impartial witness.
• Male and Females, age ≥18 years at enrollment.
• Understands and agrees to comply with planned study procedures.
• Agrees to the collection of pharyngeal swabs and blood sample as per protocol.
• Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen within one week.
• Illness of any duration, and at least one of the following:

• Radiographic infiltrates by imaging (chest x-ray)
• Clinical assessment (evidence of rales/crackles or other clinical symptoms on exam).
• Women of childbearing potential must agree to use at least one primary form of contraception for the duration of the study (acceptable methods will be determined by the site).

Exclusion criteria

• ALT/AST >5 times the upper limit of normal.
• Stage V CKD (i.e. eGFR <15 ml/min/1.73 m2 or requiring dialysis).
• Pregnant or breast feeding.
• Severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled DM, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment.
• Comorbid condition like myocardial infarction or heart failure within 90 days of recruitment.
• Prolong QT interval (>450 ms).
• Patients on invasive mechanical ventilation.